Northwestern University

Mon 12:00 PM

INVO Series in Evanston | Perspectives on Repurposed Drugs

When: Monday, March 19, 2018
12:00 PM - 1:00 PM  

Where: Ford Motor Company Engineering Design Center, ITW Classroom, 2133 Sheridan Road, Evanston, IL 60208 map it

Audience: Faculty/Staff - Student - Post Docs/Docs - Graduate Students

Contact: Sonia Kim   847.467.0446

Group: Innovation and New Ventures Office

Category: Academic


University and Industry Perspectives on Repurposing Drugs:

Successes, Pitfalls and Patent Opportunities

Join INVO for a presentation about the opportunities and challenges related to the commercialization of repurposed drugs.


Mike Moore

Director of Licensing and Life Sciences

John Haugen

Associate General Counsel


Drug repurposing is the application of already tested or approved drugs and compounds for new indications. This area saw a spike in popularity in the 1990's and 2000s with the success of drugs such as Viagra, Thalidomide, and Botox and is currently reemerging as a big opportunity highlighted by renewed interest from the NIH National Center for Advancing Translation Sciences (NCATS), patient foundations, industry and investors. In this session an overview of the patent, regulatory and other commercial considerations will be presented, alongside recent University/Industry success stories in this field.

This seminar focuses on the opportunities and challenges related to the commercialization of repurposed drugs. Michael Moore will first share a background on patents and the types of inventions that INVO has managed in this space, many of which have been generated by Feinberg researchers. John Haugen will then share his insight on strategies employed by universities and the pharmaceutical industry to capture additional intellectual property protection for drugs that are already known or on the market.

Space is limited, so be sure to reserve a spot. Please use your Northwestern email when registering.

Pizza will be served.

Register Add Event to Calendar

Add Event To My Group:

Please sign-in